Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CPO301 |
Synonyms | |
Therapy Description |
Limited information is currently available on CPO301, a putative antibody-drug conjugate (ADC) targeting EGFR (Jul 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CPO301 | CPO-301|CPO 301 | EGFR Antibody 61 | Limited information is currently available on CPO301, a putative antibody-drug conjugate (ADC) targeting EGFR (Jul 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05948865 | Phase I | CPO301 | A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 0 |